Acalabrutinib
Sign in to save this workspacePrimary targets: BTK · FDA status: FDA Approved
Selectivity scorecard
KISS
99.50
Gini
0.670
CATDS
0.044
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Acalabrutinib. Strongest target: ERBB4_HER4 at 99.9% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ERBB4_HER4 | 99.9% | 0.1% |
| 2 | BTK | 95.9% | 4.1% |
| 3 | TEC | 87.4% | 12.6% |
| 4 | BMX_ETK | 86.6% | 13.4% |
| 5 | TXK | 58.7% | 41.3% |
| 6 | ARAF | 58.3% | 41.7% |
| 7 | BRK | 52.0% | 48.0% |
| 8 | LIMK1 | 39.9% | 60.1% |
| 9 | YES_YES1 | 39.9% | 60.1% |
| 10 | CDK9_CYCLIN_T2 | 30.1% | 69.9% |
| 11 | MEK3 | 24.2% | 75.8% |
| 12 | RIPK2 | 23.3% | 76.7% |
| 13 | ERN1_IRE1 | 20.1% | 79.9% |
| 14 | BLK | 19.9% | 80.1% |
| 15 | DDR1 | 19.1% | 80.9% |
| 16 | AURORA_B | 17.9% | 82.1% |
| 17 | PKCTHETA | 17.9% | 82.1% |
| 18 | MKK6 | 17.6% | 82.4% |
| 19 | CDK9_CYCLIN_T1 | 17.1% | 82.9% |
| 20 | C_SRC | 16.9% | 83.1% |
Selectivity landscape
Where Acalabrutinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Acalabrutinib.
Atlas insights for Acalabrutinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target10%
Off-target90%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 501.36 | |
| ALLOGRAFT_REJECTION | 1851.68 | |
| ANDROGEN_RESPONSE | 414.92 | |
| ANGIOGENESIS | 233.46 | |
| APICAL_JUNCTION | 1680.57 | |
| APICAL_SURFACE | 185.04 | |
| APOPTOSIS | 1437.58 | |
| BILE_ACID_METABOLISM | 164.95 | |
| CHOLESTEROL_HOMEOSTASIS | 234.70 | |
| COAGULATION | 217.32 | |
| COMPLEMENT | 1141.80 | |
| DNA_REPAIR | 560.75 | |
| E2F_TARGETS | 1255.57 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 593.81 | |
| ESTROGEN_RESPONSE_EARLY | 567.88 | |
| ESTROGEN_RESPONSE_LATE | 521.14 | |
| FATTY_ACID_METABOLISM | 129.85 | |
| G2M_CHECKPOINT | 1146.63 | |
| GLYCOLYSIS | 481.94 | |
| HEDGEHOG_SIGNALING | 124.58 | |
| HEME_METABOLISM | 438.40 | |
| HYPOXIA | 807.70 | |
| IL2_STAT5_SIGNALING | 704.35 | |
| IL6_JAK_STAT3_SIGNALING | 700.22 | |
| INFLAMMATORY_RESPONSE | 1223.68 | |
| INTERFERON_ALPHA_RESPONSE | 156.74 | |
| INTERFERON_GAMMA_RESPONSE | 1080.04 | |
| KRAS_SIGNALING_DN | 215.65 | |
| KRAS_SIGNALING_UP | 677.52 | |
| MITOTIC_SPINDLE | 1492.03 | |
| MTORC1_SIGNALING | 809.14 | |
| MYC_TARGETS_V1 | 806.83 | |
| MYC_TARGETS_V2 | 186.15 | |
| MYOGENESIS | 866.24 | |
| NOTCH_SIGNALING | 79.74 | |
| OXIDATIVE_PHOSPHORYLATION | 233.73 | |
| P53_PATHWAY | 788.98 | |
| PANCREAS_BETA_CELLS | 71.69 | |
| PEROXISOME | 183.79 | |
| PI3K_AKT_MTOR_SIGNALING | 1865.80 | |
| PROTEIN_SECRETION | 350.74 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 95.40 | |
| SPERMATOGENESIS | 417.59 | |
| TGF_BETA_SIGNALING | 415.64 | |
| TNFA_SIGNALING_VIA_NFKB | 1081.34 | |
| UNFOLDED_PROTEIN_RESPONSE | 319.20 | |
| UV_RESPONSE_DN | 814.17 | |
| UV_RESPONSE_UP | 841.40 | |
| WNT_BETA_CATENIN_SIGNALING | 554.08 | |
| XENOBIOTIC_METABOLISM | 405.72 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.853 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.849 |
| SRR12202498 | — | 0.828 |
| SRR23303752 | — | 0.828 |
| SRR1443713 | GTEX | 0.827 |
Annotations
Sign in to read and post annotations.
Loading…